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Bisphenol A (BPA) is a high production volume monomer used for making a wide variety of polycarbonate plastics
and resins. A large body of evidence links BPA to endocrine disruption in laboratory animals, and a growing
number of epidemiological studies support a link with health disorders in humans. The aim of this review is to
summarize the recent experimental studies describing the effects and mechanisms of BPA on the female genital
tract and to compare them to the current knowledge regarding the impact of BPA impact on female reproductive
health. In particular, BPA has been correlated with alterations in hypothalamic-pituitary hormonal production,
reduced oocyte quality due to perinatal and adulthood exposure, defective uterine receptivity and the pathogenesis
of polycystic ovary syndrome. Researchers have reported conflicting results regarding the effect of BPA on
premature puberty and endometriosis development. Experimental studies suggest that BPA’s mechanism of action
is related to life stage and that its effect on the female reproductive system may involve agonism with estrogen
nuclear receptors as well as other mechanisms (steroid biosynthesis inhibition). Notwithstanding uncertainties and
knowledge gaps, the available evidence should be seen as a sufficient grounds to take precautionary actions against
excess exposure to BPA.
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There is growing concern regarding the impact of environ-
mental pollutants on animal and human reproduction [1].
For instance, a substantial number of laboratory rodent
studies suggest that the plasticizer Bisphenol A (BPA) may
act as a reproductive toxicant, although many uncertainties
remain as to the actual risk for humans [2]. BPA is one of
the highest volume chemicals produced world-wide and is
used in the manufacture of plastics and epoxy resins that
are pervasive in our environment and in our daily lives [3].
BPA has estrogenic activity and binds to the α- and, to a
lesser extent, β-estrogen receptors (ER) in vitro and in vivo
[4]. Moreover, BPA can also inhibit the activity of endogen-
ous estrogens and/or disrupt estrogen nuclear hormone re-
ceptor action [5]. There is additional clear evidence of a* Correspondence: donatella.caserta@uniroma1.it
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unless otherwise stated.17β-estradiol, BPA, and diethylstilbestrol (DES) membrane-
binding site with a pharmacologic profile that differs from
the classical ER. This membrane receptor may be impli-
cated in triggering non-genomic actions of xenoestrogens
and it has been demonstrated its existence both in pancre-
atic β cells and in pancreatic α cells [6].
BPA also affects other relevant endocrine activities, in-
cluding the thyroid hormone pathway and binding to
glucocorticoid and androgen receptors as well as more
complex interferences with the central nervous system
and immune system [3,5].
In experimental studies, BPA has been shown to affect
many reproductive indices, such as ovary, uterus and
vagina weights (indicating estrogenic action); egg shape;
fertilization rate; number of live-born neonates per lit-
ter; distance between the genital pore and the anus in
newborns (indicating the degree of masculinization or
feminization of external genitalia); time of vaginal open-
ing (indicating the start of female puberty); and onset ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The evidence in the literature suggests that BPA expos-
ure in humans may impair fertility [10].
In fact, we recently observed that women with BPA
concentrations above the limit of detection were signifi-
cantly more represented in the infertile population than
in healthy controls [11]. In the last years, a few reviews
have been published regarding the impact of BPA on hu-
man health [12-14]. These data are mainly derived from
epidemiological studies, even though cross-sectional
analyses cannot establish causality [15]. Furthermore, in
human studies the possibility of an additive effect with
other prevalent endocrine disrupting compounds should
not be overlooked [13].
To the best of our knowledge, despite the vast literature
of experimental animal and mechanistic studies, there are
no reviews summarizing the toxicological studies regarding
BPA’s effect on the female reproductive system. The aim of
the present review is to synthetize and evaluate the experi-
mental evidence regarding the impact of BPA on the female
genital tract and to relate this evidence to the current
knowledge of BPA’s effect on human reproduction.
In particular, we focused on the effect of BPA on the
hypothalamic-pituitary-ovarian axis (HPOA), the ovary,
the uterus and the development of diseases, such as
polycystic ovarian syndrome and endometriosis.
Methods
A systematic MEDLINE (PubMed) search was performed
using the following keywords: “BPA”, “endocrine disrup-
tors”, “fertility”, “reproductive health”, “genital tract”, “BPA
and fertility”, “GnRH alterations and BPA”, “BPA and pu-
berty onset”, “BPA and oocytes”, “BPA and primordial fol-
licles”, “BPA and uterus”, “BPA and polycystic ovarian
syndrome” and “BPA and endometriosis”. Relevant articles
published in the last 10 years (from 2004 since November
2013) were selected. We considered experimental studies,
epidemiological studies and previous reviews. Criteria for
inclusion and exclusion were established before the biblio-
graphic search. Studies published in languages other than
English were considered if an English abstract was avai-
lable. When evaluating experimental studies, we did not
consider studies in which the effects of perinatal exposure
were analyzed on the second generation. Moreover, stu-
dies in which BPA was administered with other endocrine
disruptors were not considered as the aim of this study
was to examine the potential direct association of BPA
with female reproductive disorders; therefore, a discussion
on the complex issue of the “cocktail” effects of endocrine
disorders is outside the scope of this paper.
BPA actions on the hypothalamic-pituitary-ovarian axis
During critical periods of prenatal and postnatal deve-
lopment, the hormonal milieu is crucial for the correctorganization of neuroendocrine circuits that coordinate
sex-specific physiology [16]. BPA exposure has been asso-
ciated with alterations in brain sexual differentiation and
modifications in the expression of gonadotropin-releasing
hormone (GnRH), hypothalamic ER and luteinizing hor-
mone (LH) [16-18].
Altered brain sexual differentiation has been demon-
strated in perinatally treated rodents. In particular, BPA has
been shown to alter the composition of the following two
sexually dimorphic areas located in the hypothalamus: the
sexually dimorphic nucleus (SDN) and the anteroventral
periventricular nucleus (AVPV) [19]. BPA’s endocrine dis-
rupting action could explain this effect; however, an epigen-
etic mechanism has been hypothesized as well [19]. Indeed,
Kundakovic et al. [20] observed that in the hypothalamus
of female offspring treated during gestation, the ER-α gene
(Esr1) was hypomethylated for a downregulation of DNA
methyltransferase 1 (DNMT1), an epigenetic regulator.
However, unexpectedly, hypomethylation was associated
with decreased Esr1 mRNA levels, suggesting that add-
itional mechanism are involved in the transcriptional
regulation of this gene [20].
The AVPV nucleus is fundamental for gonadotropin re-
lease and the LH surge [16-18]. The neural circuit that co-
ordinates reproductive function is sexually differentiated;
the female AVPV is nearly twice the size of the male
AVPV, and neurons that express tyrosine hydroxylase
(TH, rate-limiting enzyme for dopamine synthesis) are
more abundant [17,19]. These sex differences are due to
female development occurring in the absence of estrogen,
whereas the perinatal male brain is exposed to high levels
of estrogens synthesized locally through the aromatization
of testicular testosterone [17]. Indeed, during critical pe-
riods of perinatal development, aromatase is present in
specific brain regions [18].
Contrasting results have been reported regarding the ef-
fect of BPA on the number of TH-positive cells. Rubin
et al. [18] observed a significant decrease in the number of
TH-positive cells in the female population and no differ-
ences in males, while Patisaul [17] found an increased in
the number of TH-positive cells in the male population.
Such differences may be attributed to the species (rat or
mouse in [17] and [18], respectively) or to the develop-
mental exposure window (only neonatal or from organo-
genesis to neonatal in [17] and [18], respectively). AVPV-
TH-containing neurons interact with GnRH fibers and
modulate GnRH production [19]. GnRH secretion is pul-
satile and acts on gonadotrope cells of the anterior pituit-
ary to stimulate the synthesis and release of LH and
follicle-stimulating hormone (FSH). The frequency of the
GnRH pulses determines the predominant hormone pro-
duced. LH is produced with fast GnRH pulses, and FSH is
favored with slow pulse frequencies [21]. Fernandez et al.
[21] observed that female rats exposed to BPA during the
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an increased number of peaks. Nevertheless, LH release in
their study was lower basally and after GnRH stimulation,
suggesting a qualitative, rather than quantitative, alteration
in the gonadotrope hormone production. Monje et al. [16]
even found that rats exposed in the neonatal period were
incapable of producing an estradiol-induced LH surge.
The decrease in basal and GnRH-induced LH release
caused by BPA may be the consequence of the increased
GnRH pulse frequency leading to a desensitization of
the pituitary. Alternatively, a direct effect of BPA on LH
secretion may occur [21]. Kisspeptins (KiSS) are critical
hypothalamic regulators of GnRH secretion [22]. BPA ex-
posure in rodents may alter the KiSS-regulation of the LH-
surge system via a different mechanism that is dependent
on the developmental window. Acute neonatal exposure
seems to lead to downregulation [23], whereas prolonged
perinatal (prenatal to neonatal) treatment seems to elicit an
up-regulation of KiSS-positive AVPV cells in male rats [24].
Indeed, Xi et al. [25] observed that in mouse pups exposed
to BPA both in utero (starting from gestation day 1) and
postnatally (21–49), the expression levels of KiSS-1 mRNA
were increased. Conversely, for pups exposed only postna-
tally (21–49) no noticeable changes in gene expression
levels were detected, indicating a higher susceptibility dur-
ing the prenatal window.
Overall, an influence of BPA-induced HPOA changes on
the time of pubertal onset is plausible. Some studies have
observed that early vaginal opening occurs in BPA-treated
rodents (a sign of advanced puberty onset) [9,21]. This
event may be explained by a premature hypothalamic-
pituitary maturation induced by BPA treatment during the
pre- and/or postnatal windows. However, the few human
studies do not provide consistent results regarding a pos-
sible effect of BPA on pubertal development. Wolff et al.
[26] investigated the association of exposure to phenols,
phthalates, and phytoestrogens with pubertal stages in a
multiethnic longitudinal study of 1,151 girls. They found
that these endocrine-active agents had only limited associ-
ation with pubertal development. In particular, the authors
observed some weak association with phthalates and phy-
toestrogens but not with phenols. Conversely, in a case–
control study by Qiao et al. [27], girls with premature pu-
berty had significantly higher BPA serum levels. Therefore,
the relationship between exposure to BPA and puberty on-
set in humans is still largely unknown. It should be noted
that most animal studies were planned to gain mechanistic
insights; thus, subcutaneous injection was often used, and
in some cases, the administered doses were quite high.
Upon real-life exposure by ingestion, dermal contact or
inhalation, the majority of BPA is conjugated to BPA-
glucuronide in the liver, which is a form devoid of inter-
action with nuclear receptors [28]. More experimental
studies are needed to investigate BPA effects on HPOAand puberty onset using treatment routes and dose levels
relevant to human environmental exposures. Table 1
shows BPA effects on the hypothalamic-pituitary-ovarian
axis in animal experiments.
BPA actions on the ovary
As already noted for the actions on the HPOA, BPA has
different effects on the ovary depending on the time of
exposure.
Maternal exposure affects the earliest stages of oogenesis
in the developing fetal ovary. The resulting meiotic defects
increase the likelihood that embryos produced by the ex-
posed females in adulthood will be chromosomally abnor-
mal. In particular, several studies on in utero exposure of
mice as well as rhesus monkeys revealed disturbances dur-
ing the prophase events of meiosis and an increase in mul-
tiple oocyte follicles (MOFs) [29-31].
Disturbances during prophase events seem to mainly
involve synapsis and recombination between homolo-
gous chromosomes. An interesting study by Susiarjo
et al. [31] on pregnant mice exposed to BPA revealed
synaptic abnormalities, such as “incomplete synapsis”
(partial or complete synaptic failure of a single chro-
mosome pair), end-to-end associations between non-
homologous chromosomes and an increased risk of
aneuploidy.
MOF occur due to improper cyst breakdown. In fact,
in rodents, oocytes at birth are clustered in cysts and in-
dividual primordial follicles become detectable only
when the cysts breakdown 3–5 days after birth. Usually,
the cyst breakdown is initiated upon decreased estrogen
levels after birth. BPA, acting as a synthetic estrogenic
compound, may counteract this event [29,32,33]. Fur-
thermore, gene ontology analysis suggests that BPA acts
to downregulate genes involved in the mitotic cell cycle,
raising the possibility that fetal BPA exposure may limit
expansion of the primordial germ cell population [34].
Intrauterine exposure to BPA elicits analogous effects
on early oogenesis and follicle formation in mice [29,31]
as in rhesus monkeys [30]. This mammal is considered a
valid model for human reproductive physiology [30];
hence, the findings of experimental studies raise con-
cerns about the impact of BPA exposure on human re-
productive programming.
Most studies conducted on rodents exposed to BPA
during the early postnatal period report an initial follicle
recruitment with a consequent decrease in the primor-
dial follicle reserve as well as an increased incidence of
MOFs [33,35,36]. These results were obtained even in a
study conducted on lambs, a species in which the fol-
licular development trajectory is similar to humans [32].
Follicle activation has been confirmed by Chao et al.
[36], who found that upon BPA exposure, mouse ovar-
ies had significantly decreased primordial follicles but
Table 1 BPA effects on the hypothalamic-pituitary-ovarian axis in animal experiments
Study Sample Dose Route of administration Time of
exposure
Results
Monje et al. [16] Female rats 0.05, 20
mg/kg day
Subcutaneous injections PND 1-7 BPA20 group no production of estradiol-induced LH surge;
ERα expression increased in AVPV and decreased in arcuate
nucleus (ARC); PR expression decrease in AVPV
Patisaul et al. [17] Rat offspring 250 μg
every 12 h
Subcutaneous injections PND 1-2 Increased number of TH-positive cells in the male population







GD 8- d 16
of lactation
BPA; 250 female offspring; significantly decreased number of
TH-positive cells; alterations in sexually dysmorphic behavior




Oral administration GD O-19 Upregulation of Dnmt3a mRNA in the male prefrontal cortex
correlated with hypermethylation of the Esr1 gene;
downregulation of Dnmt1 in the female hypothalamus
associated with hypomethylation of the Esr1 gene; decreased
Esr1 expression in the male prefrontal cortex and in the
female hypothalamus; changes in social, exploratory and
anxiety-like behavior.







PND 1-10 BPA500 significantly lower serum LH basally and after
GnRH stimulation; alterations in GnRH pulsatility; advanced
puberty onset




Subcutaneous injections PND 1-5 Decreased expression level of hypothalamic KiSS-1
mRNA at the prepubertal stage
Bai et al. [24] Male rat
offspring
2 μg/kg Subcutaneous injections GD 10- d 7
of lactation
Up-regulation of KISS-positive AVPV cells in prepubertal,
pubertal, and adult male rats exposed perinatally to BPA








Dose-dependent increases in the expression levels of KiSS-1,
GnRH and FSH mRNA in BPA-exposed female and male pups;
inhibition in the expressions of testicular steroidogenic enzymes
and the synthesis of testosterone in the male pups; greater
aromatase expression level and synthesis of estrogen in the
female pups
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contrast with other studies, Karavan et al. [33] ob-
served an increased percentage of primordial follicles
in neonatal mice injected with BPA during the first
four postnatal days and examined on postnatal day 5.
Table 2 shows effects of pre and postnatal BPA expos-
ure on oocytes
In a recent study conducted by Lee et al. on adult female
rats (8 weeks of age) exposed orally to 1 μg/kg body weight
(BW) or 100 μg/kg BW for 90 days, caspase-3 activation
was significantly increased by BPA exposure, causing an
augmentation of follicular atresia and luteal regression [37].
BPA-induced apoptosis in granulosa cells has already been
reported by Whetherill et al. [5], but the precise mechanism
remains unclear. In addition, Lee et al. observed that 17β-
estradiol synthesis was decreased via downregulation of
aromatase. The steroidogenic acute regulatory protein
(StAR) and aromatase cytochrome P450 (P450arom) ap-
peared to be targeted by BPA [37]. The occurrence of
negative effects on the ovary using lower doses of BPA
(1 μg/kg BW), rather than the doses used in other ex-
periments, should trigger further studies.
In vitro studies have demonstrated that BPA can inter-
fere with ovarian hormone production.
A study conducted on antral follicles isolated from 32-
day-old mice proved that BPA significantly decreasedprogesterone, dehydroepiandrosterone, androstenedione,
estrone, testosterone, and estradiol production [38]. Be-
cause the BPA’s mechanism of action of is life stage-
dependent, it cannot be excluded that BPA exposure close
to or during sexual maturity mainly elicits an inhibiting
action on steroid biosynthesis. This inhibitory effect has
been observed even in isolated porcine granulosa cells
[39] and in human luteal cells obtained from the corpora
lutea of woman undergoing surgery for non-endocrine
gynecological diseases [40]. In both studies, incubating
cells with 0.1, 1, and 10 μM of BPA induced a significant
decrease in progesterone production. Conversely, no in-
hibitory action was observed in a study by Dominuigez
et al. [41] conducted on human granulosa-lutein cells col-
lected from women undergoing in vitro fertilization (IVF)
treatments. Instead, an increased metalloproteinase 9
(MMP-9) secretion was observed, suggesting a BPA effect
on the stability of the ovarian extracellular matrix.
In vitro studies have also been conducted on human oo-
cytes [42,43]. Genes involved in DNA double-strand gener-
ation, signaling and repair were up-regulated in fetal oocytes
exposed to BPA [42]. Machtinger et al. [43] treated human
oocytes obtained from patients undergoing IVF cycles with
0, 20, and 200 ng/ml BPA. In accordance with animal stud-
ies, they observed a negative effect on cell cycle progression,
spindle architecture and chromosome organization.
Table 2 Effects on oocytes of prenatal and postnatal BPA exposure





Zhang et al. [29] Pregnant mice 0.02, 0.04,
0.08 mg/kg
bw/day
Oral route 12.5-18.5 day
post-coital
Inhibition of meiotic progression to prophase I in 0.08 BPA treated
group; decreased mRNA expression of specific meiotic genes;
inhibition of germ cell cyst breakdown





tubing implants GD 50–100,
GD 100 to term
Disturbances in prophase events; increase in MOFs
Susiarjo et al.[31] Pregnant mice,
offspring
400 ng/day pellets releasing
BPA
GD 11.5-17.5 Aberrant meiotic prophase; increased aneuploidy in eggs and
embryos from adult females
Rivera et al. [32] Lambs 50 μg/kg/day Subcutaneous
injections
PND 1-14 Decreased ovarian weight; increased primordial-to-primary follicle
transition; increased incidence of MOFs; increased number of small
antral atretic follicles associated with higher p27 expression




PND 1-4 Increased incidence of MOFs; increased total number oocytes;
increased percentage of primordial follicles




PND 1-7 In BPA 20 group stimulation of neonatal initial follicle recruitment;
p27 and ERα increased expression; increased proliferation rate of
granulosa cells





Decreased methylation pattern of two maternal imprinted genes;
upregulated mRNA expression of ERα; decreased primordial follicle
number but increased primary, secondary and antral follicle
number; abnormal spindle assembling in meiosis
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and on human oocytes in vitro may explain the poor ova-
rian response to IVF treatments and the recurrent mis-
carriages observed in women with higher serum BPA
concentration [12]. In particular, increased BPA levels are
correlated with a decrease in peak estradiol levels and de-
creased oocyte retrieval number [10,44]. A similar mechan-
ism of action may underlie the association between female
infertility and higher BPA levels that has been consistently
reported in the results of the Italian biomonitoring study
PREVIENI [11,45]. Interestingly, in this study, the higher
serum BPA levels in infertile women were also correlated
with upregulation of some nuclear receptors (ERα, ERβ,
Androgen receptor, and Pregnane-X receptor) in the serum
mononuclear cells [11,45]. It is still unclear whether chem-
ical compounds are linked with first-trimester spontaneous
abortion [46]. Some studies reported a higher serum BPA
concentration in women with recurrent miscarriages com-
pared to healthy controls [46,47]. Zheng et al. [47] even ob-
served that the risk of unexplained recurrent spontaneous
abortion increased progressively with increasing serum
BPA levels. Sugiura-Ogasawara et al. [46] suggested that
the mechanism leading to an increased incidence of mis-
carriages from BPA exposure is an increase in embryonal
chromosome abnormalities.
BPA and its actions on the uterus
Mendoza-Rodriguez et al. [48] showed that when BPA was
administered to rats in their drinking water (approximate
dose 1.2 mg/kg BW/day) during pregnancy and lactation,
there was a resultant significant increase in the thickness of
the uterine epithelia and stroma in the adult femaleoffspring. The majority of BPA-exposed offspring also had
reduced epithelial apoptosis and a downregulation of α-
estrogen receptor expression in epithelial cells during es-
trus. In vitro studies show that BPA in other endometrial
cells seems to induce different effects. Indeed, decreased
proliferation was observed both in human endometrial fi-
broblasts isolated from hysterectomy specimens [49] and in
human endometrial endothelial cells [50]. In particular, in
the latter case, the authors found that mRNA levels of gene
products involved in the cell cycle, cell division and cyto-
skeletal organization were affected [50].
Although BPA is not a genotoxic carcinogen, a possible
endocrine-related tumorigenic effect might be elicited by
BPA exposure during critical periods of differentiation.
Atypical hyperplasia, stromal polyps of the uterus as well as
sarcoma of the uterine cervix were observed in adult female
offspring of mice injected with BPA during organogenesis.
These lesions were completely absent in controls: however,
the incidence was low and did not show a meaningful
dose–response relationship; therefore, no conclusion could
be drawn [51]. Nevertheless, the increased proliferative ac-
tivity and reduction of programmed cell death in uterine
epithelial cells upon intrauterine exposure, as observed in
BPA-exposed rats by Mendoza-Rodriguez et al. [48], may
support an increased predisposition to cancer and/or a
tumor-promoting effect [48]. In contrast with these results,
human epidemiological studies do not seem to support the
relationship between BPA and endometrial disorders [12].
Indeed, Hiroi et al. [52] unexpectedly found that in patients
with complex endometrial hyperplasia, serum BPA was sig-
nificantly lower compared to both the control and simple
endometrial hyperplasia groups. Even in postmenopausal
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lower than either the control or simple endometrial hyper-
plasia groups.
There is a growing body of literature to suggest that BPA
exposure may lead to defective uterine receptivity [53-55].
Varayoud et al. [53] observed a lower pregnancy rate and a
reduction of implantation sites (live fetuses plus resorption
sites) in female rats injected with BPA during the first post-
natal week. Downregulation of homeobox A10 (Hoxa10)
expression may explain, at least in part, the defective uter-
ine receptivity. A different effect was observed by Bromer
et al. [54] in mice from dams injected in utero during or-
ganogenesis (gestation days 9–16). In these cases Hoxa10
up-regulation and increased binding of ERα to the Hoxa10
Estrogen Responsive Element (ERE) were observed. As in
other instances, it cannot be excluded that the discrepancy
between effects observed in [53] and [54] is due to the dif-
ferent exposure windows, i.e., neonatal vs. prenatal, respect-
ively. Alternatively, the drop in implantation rate could be
due to a direct BPA effect on the development and transport
of the pre-implantation embryo [55]. However, this possible
explanation is less likely because the adverse effects of BPA
mostly result from endocrine modulation rather than from
target cell toxicity. An influence of BPA exposure on im-
plantation success can also be surmised. Indeed, it has been
observed that women with higher urinary BPA had higher
implantation failure during IVF treatments [56]. Table 3
shows BPA effects on the uterus in animal experiments
BPA and polycystic ovary syndrome (PCOS)
PCOS is the most common endocrinopathy among women
of reproductive age. It is characterized by hyperandro-
genism, insulin resistance and chronic anovulation. A role
for BPA as an endocrine disruptor in the pathogenesis of
PCOS has been recently proposed [57]. Several studiesTable 3 BPA effects on the uterus in animal experiments











Mice 0.1 (BPA 0.1), 1 (BPA 1),
10 (BPA10), 100 (BPA 100),





Female rats 0.05 (BPA 0.5), 20









Xiao et al. [55] Pregnant mice 0, 0.025, 0.5, 10, 40,
100 mg/kg/day
Subcutaneous
injectionshave reported higher BPA levels in premenopausal
women with PCOS when compared to regularly ovulat-
ing women [57,58]. In addition, BPA treatment in rats,
both during gestation or during the neonatal period, in-
duced the development of a PCOS-like syndrome in
adulthood [49,59].
A bidirectional mechanism has been hypothesized to
underlie the relationship between PCOS and BPA, involv-
ing both BPA-increased insulin resistance and free andro-
gen index as well as chronic, low-grade inflammation [57].
In fact, Kandaraki et al. [58] found a significant positive as-
sociation between testosterone and androstenedione with
BPA levels in women with PCOS. The increase in the an-
drogen level may be explained by different mechanisms.
The exposure of rat ovarian theca-interstitial cells to BPA
in vitro results in elevated testosterone synthesis [58]. The
increase in GnRH/LH pulse frequency observed in BPA ex-
periments, as mentioned above, may be involved in this
event [21]. Moreover, BPA alters androgen metabolism in
the liver and acts as a potent ligand of sex hormone-
binding globulin (SHBG); thus, it can displace androgens
from SHBG resulting in increased levels of serum free an-
drogens [58]. However, some studies have hypothesized
that elevated BPA is a consequence and not a cause of
PCOS because women with PCOS have higher circulating
testosterone levels than do healthy women, and elevated
androgen concentrations decrease BPA clearance [59].
BPA and endometriosis
Endometriosis is a gynecological disorder characterized
by endometrial glands and stroma that grow outside the
uterine cavity. This ectopic endometrium responds to
hormonal signaling; therefore, fetal exposure to estro-







BPA offspring: irregular estrous cycles; significant increase in
the thickness of uterine epithelium and stroma; modifications
in apoptotic patterns of uterine epithelium and ERα downregulation
GD 9-16 Adenomatous hyperplasia in BPA1 and BPA100 not in controls;
atypical hyperplasia in BPA 0.1, BPA 1, BPA 1000 not in controls;
endometrial polyps in BPA 0.1, BPA 1, BPA 10; stromal sarcoma
in one BPA 100 mouse
PND 1,3,5,7 Pregnancies were not established in 10% of BPA 0.5 and in 23%
of BPA 20, whereas in the controls the pregnancy rate was
100%; decreased number of implantation sites in BPA20; lower
ERα and PR expression; lower expression of Hoxa10
GD 9-16 Hoxa10 increased expression; decreased DNA methylation in the
promoter and in intron regions of Hoxa10 with consequent
increase in binding of ER-α to Hoxa10 ERE
GD 0.5-3.5 No implantation sites in BPA 100 treated group; smaller
implantation sites, increased gestation period, reduced postnatal
survival rate in 40 BPA treated group; alterations in PR expression.
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volved in the occurrence of estrogen-dependent patholo-
gies. Strong epidemiological data link in utero exposure
to the potent estrogen-mimicking drug DES and the oc-
currence of endometriosis later in adult life [60]; how-
ever, much less is known about exposure to BPA. In a
pilot study, Cobellis et al. [62] investigated the possible
relationship between serum levels of both BPA and the
closely related, albeit much less investigated, bisphenol B
(BPB) and the occurrence of endometriosis. These authors
did not find BPA or BPB in any of the sera of healthy con-
trol women (n = 11). In contrast, the researchers found at
least one of the bisphenols in 63.8% of sera of the 58 pa-
tients with endometriosis; 51.7% and 27.6% of these sam-
ples had detectable BPA or BPB levels, respectively, while
15.5% of patients had detectable levels of both bisphenols.
In a study conducted on 465 women undergoing laparos-
copy/laparotomy and 131 patients with endometriosis di-
agnosed by pelvic resonance imaging, Buck Louise et al.
[63] found a positive association between urinary phtha-
lates and endometriosis, while urinary BPA was not asso-
ciated with endometriosis. In addition, Itoh et al. [64]
analyzed the total urinary BPA concentration of 166 in-
fertile patients and did not observe any association with
endometriosis. It cannot be overlooked that different
biomarkers of exposure may have different meanings.
Therefore, the urinary BPA concentration (as used in
[63] and [64]) provides information on the overall envir-
onmental exposure, while serum BPA [62] may be a
more direct indicator of the internal exposure of target
tissues, as outlined in the PREVIENI study on infertile
Italian women [11,44].
A study on mice suggested a possible mechanism by
which exposure to BPA may result in a predisposition to
endometriosis. Signorile et al. [61] injected pregnant mice
with BPA (100 and 1000 μg/kg/day) from day 1 of gesta-
tion to 7 days after delivery and found endometriosis-like
structures in the adipose tissue surrounding the genital
tract of a number of their sexually mature (3 month-old)
offspring. Only one case was observed in the control
group. Therefore, the authors suggested that endometri-
osis may be caused by alterations in the proper axial de-
velopment of the Mullerian system during embryogenesis
by changes in genetic-epigenetic programming. As pre-
viously mentioned, studies using parenteral routes of
administration may have limited, or even no, relevance
to human risk assessment. On the other hand, contrary
to experimental studies, the human cross-sectional
studies cannot give any insight on a possible effect on
programming.
Considering the conflicting results, the hypothesis of a
relationship between BPA and endometriosis needs to be
further explored by robust and soundly designed human
biomonitoring studies.Conclusions
An increasing number of studies indicate that exposure to
BPA is associated with a variety of disorders of the female
reproductive system. Toxicological risk assessment of the
potential human health effects rely mainly on experimen-
tal studies that should be methodologically robust and
provide information on exposure routes and levels rele-
vant to humans but also on epidemiological studies, when
available [15]. In this appraisal of the recent literature, we
aimed to integrate and compare the results of both labora-
tory and human studies on BPA, which is among the most
widespread endocrine disrupters. In relation to effects on
the HPOA, animal experiments revealed alterations in
brain sexual differentiation, higher GNRH pulsatility, al-
terations in the estradiol-induced LH surge and advanced
puberty onset, as demonstrated by an early vaginal open-
ing [16-18,21]. However, in women, the influence of BPA
on the pathogenesis of premature puberty has not been
confirmed. Some authors found a correlation between pu-
bertal stages and the BPA serum level [27], while others
observed conflicting results [26].
The higher risk of infertility and poor ovarian response
to IVF treatments described in women with higher BPA
concentrations suggest effects on oocyte quality and
ovarian function in women [4,10,12,44,45]. In experi-
mental studies, perinatal exposure has revealed distur-
bances in prophase events, and an increase in MOFs
and initial follicle recruitment with increased numbers
of primary, secondary and antral follicles [29-33,35,36].
In vitro studies on ovarian cells isolated from the ovary
of both animals and women have also demonstrated an
inhibiting action on steroid biosynthesis [38-40]. Thus,
human and animal data show a degree of consistency.
BPA may reduce apoptosis and increase proliferation in
the endometrium of perinatally exposed rats [48]; how-
ever, no tumorigenic effect of BPA on the uterus has been
shown in adult women [52]. Additionally, rodent studies
reported a defective uterine receptivity [53,55]; this event
may be related to the higher risk of infertility or implant-
ation failure observed during IVF treatments.
It has been suggested that BPA may be involved in the
occurrence of some gynecological diseases. The associ-
ation between BPA exposure and PCOS is supported by
both human studies [57,58] and in vivo animal studies
[49,59]. Indeed, BPA may induce an increase in androgen
levels, while androgens decrease BPA clearance [57-59].
On the other hand, the involvement of BPA in the patho-
genesis of endometriosis is doubtful; endometriosis-like
structures were detected in mice perinatally injected with
BPA [61]. Conversely, epidemiological studies did not
yield consistent results [63,64]. Differences between la-
boratory evidence and epidemiological study results may
be due to BPA dose, to the route of administration and to
the time of exposure. Humans are exposed to BPA in a
Caserta et al. Reproductive Biology and Endocrinology 2014, 12:37 Page 8 of 10
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gestion of contaminated food or water. Conversely, in most
of the experimental studies reported in this review, BPA is
administered only for a limited period through parenteral
treatments. On the other hand, experimental studies allow
a more detailed study of molecular events in target tissues,
and, most important, allow for the investigation of long
term effects of developmental exposures, which are im-
portant for BPA as well as for other endocrine disrupters.
For obvious ethical reasons, controlled studies of the
long-term exposure effects cannot be performed on preg-
nant women or children. The experimental studies pro-
vide some important information, namely, the BPA mode
of action in some reproductive tissues may be highly
dependent on the window of exposure [17,18,53,54]. The
effects on HPOA [16-18,21], steroid biosynthesis in the
ovary [37-40], or androgen-SBHG binding [57,58] clearly
show that the potential harmful effects of BPA on female
reproduction are more complex than “estrogenic” action.
As for human biomonitoring studies, more insight would
be gained by a consistent use of the biomarkers of expos-
ure, e.g., urine vs serum [62-64]; the integration of the bio-
markers of exposure with molecular markers of endocrine
action [11,45,58]; and the use of bio-banks to investigate
long-term effects.
Although the association between BPA exposure and
some gynecological disorders is still doubtful, there is
currently sufficient evidence to prompt precautionary
actions against excess exposure to BPA.
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